Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Figure 5 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Walter M. Gregory, Thomas J. Prior, J. Blake Bartlett, Pieter Sonneveld, Meletios A Dimopoulos, Philippe Moreau, Saad Z. Usmani, Thierry Façon (2025). Figure 5 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential. , DOI: https://doi.org/10.1158/1078-0432.29221463.
Preprint37 days agoSupplementary Data 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Walter M. Gregory, Thomas J. Prior, J. Blake Bartlett, Pieter Sonneveld, Meletios A Dimopoulos, Philippe Moreau, Saad Z. Usmani, Thierry Façon (2025). Supplementary Data 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential. , DOI: https://doi.org/10.1158/1078-0432.29221457.
Preprint37 days agoFigure 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential
Walter M. Gregory, Thomas J. Prior, J. Blake Bartlett, Pieter Sonneveld, Meletios A Dimopoulos, Philippe Moreau, Saad Z. Usmani, Thierry Façon (2025). Figure 1 from Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative Potential. , DOI: https://doi.org/10.1158/1078-0432.29221475.
Preprint37 days agoMM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial
Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Façon, Cesar Rodriguez, Ralph Wäsch, Meletios A Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab (2025). MM-099: Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results From the CC-92480-MM-002 Trial. , 25, DOI: https://doi.org/10.1016/s2152-2650(25)02558-3.
Article37 days agoPositron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.
Elena Zamagni, Thierry Façon, Meletios A Dimopoulos, Xavier P. Leleu, Meral Beksaç, Luděk Pour, Roman Hájek, Zhuogang Liu, Jiří Minařík, Philippe Moreau, Joanna Romejko‐Jarosińska, Ivan Spicka, Tom Martin, Lugui Qiu, Christos Sachpekidis, Ercem Kodas, Helgi van de Velde, Liang Zhao, Robert Orlowski, Hartmut Goldschmidt (2025). Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.7551.
Article37 days ago